

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-7. (Cancelled)

8. (Previously presented) An isolated polynucleotide sequence encoding a polypeptide comprising an anti-carcinoembryonic antigen (anti-CEA) antibody ("806.077 Ab") comprising complementarity determining regions (CDRs) in which the CDRs comprise the following sequences:

a) heavy chain

CDR1 DNYMH (SEQ ID NO: 29)

CDR2 WIDPENGDTE YAPKFRG (SEQ ID NO: 31)

CDR3 LIYAGYIAMD Y (SEQ ID NO: 32); and

b) light chain

CDR1 SASSSVTYMH (SEQ ID NO: 26)

CDR2 STSNLAS (SEQ ID NO: 27)

CDR3 QQRSTYPLT (SEQ ID NO: 28)

12 9. (Previously presented) A vector comprising a polynucleotide as defined in claim 8, 20, 21, 22, 23 or 24. 11  
9, 10

2 ~~16~~. (Previously presented) A host cell transformed with a polynucleotide sequence as defined in claim ~~8~~.

11-15. (Cancelled)

3 ~~16~~. (Previously presented) A polynucleotide sequence encoding a polypeptide comprising an antibody conjugate comprising an antibody as defined in claim ~~8~~ and an effector moiety.

4 ~~17~~. (Previously presented) A vector comprising a polynucleotide sequence as defined in claim ~~16~~.

5 ~~16~~. (Previously presented) A host cell transformed with a polynucleotide sequence as defined in claim ~~16~~.

6 ~~19~~. (Currently amended) A method of making a conjugate as defined in claim ~~16~~, which comprises:  
subjecting a host cell, ~~a transgenic non-human mammal or a transgenic plant as defined in claim 18~~ to conditions conducive to expression of the antibody conjugate.

7 ~~20~~. (Previously presented) A polynucleotide sequence encoding a polypeptide comprising an antibody as defined in claim ~~8~~, wherein the heavy chain CDRs 1 and 3 are further defined as:

CDR1 FNIKDNYMH (SEQ ID NO: 30); and

CDR3 HVLIYAGYLA MDY (SEQ ID NO: 33).

8 21. (Previously presented) A polynucleotide sequence  
encoding a polypeptide comprising an antibody as defined in claim  
18, said antibody comprising the following structure:

a heavy chain variable region sequence (SEQ ID NO:11)

EVQLQQSGAE LVRSGASVKL SCTASGFNIK DNYMHWVKQR 40

PEQGLEWIAW IDPENGDTEY APKFRGKATL TADSSSNTAY 80

LHLSSLTSED TAVYYCHVLI YAGYLAMDYW GQGTSVAVSS 120

and

a light chain variable region sequence (SEQ ID NO:9)

DIELTQSPAI MSASPGEKVT ITCSASSSVT YMHWFFQQKPG 40

TSPKLWIYST SNLASGVPAR FSGSGSGTSY SLTISRMEAE 80

DAATYYCQQR STYPLTFGAG TKLELKRA 108 •

10 22. (Previously presented) A polynucleotide sequence  
encoding a polypeptide comprising a humanized antibody as defined  
in claim 23 said antibody comprising at least one of the  
following sequences:

a heavy chain variable region sequence which is VH1 (SEQ ID  
NO:55);

a light chain variable region sequence which is VK4 (SEQ ID  
NO:71);

a human CH1 heavy chain IgG3 constant region;

a human kappa light chain CL region; and

a human IgG3 hinge region.

9 ~~23~~ (Previously presented) The polynucleotides sequence of  
claim ~~21~~, wherein said antibody is a humanized antibody.

10 ~~24~~ (Previously presented) The polynucleotide sequence of  
claim ~~22~~, wherein said antibody is in the form of an  $f(ab')_2$   
fragment.